Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6

WEBINAR Transdisciplinary Immunology Journal Club
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Lyu A & al. Nature. 2025 
With Dr Simon COIBA
Thursday, April 24, 2025 from 5:00 PM to 6:00 PM
REGISTRATION here >> to get the ZOOM link!

Revoir en Replay TIJC#5
Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division (Nat Immunol.) par le Dr Matthieu Roulleau Dugage, disponible ICI

Revoir en Replay TIJC#1
JAK Inhibitors and Cancer: Friend or Foe? Par le Dr Samuel Bitoun, disponible ICI

Revoir en Replay TIJC#2
The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer, Nature 2024. Par le Dr François-Xavier Danlos, disponible ICI

Revoir en Replay TIJC#3
Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis, JExpMed. 
With Dr Marie ROBERT. REPLAY HERE !